[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PL2001466T3 - Rapamycyna w małej dawce do leczenia chorób związanych z przepuszczalnością naczyń - Google Patents

Rapamycyna w małej dawce do leczenia chorób związanych z przepuszczalnością naczyń

Info

Publication number
PL2001466T3
PL2001466T3 PL07753937T PL07753937T PL2001466T3 PL 2001466 T3 PL2001466 T3 PL 2001466T3 PL 07753937 T PL07753937 T PL 07753937T PL 07753937 T PL07753937 T PL 07753937T PL 2001466 T3 PL2001466 T3 PL 2001466T3
Authority
PL
Poland
Prior art keywords
treatment
low
related diseases
vascular permeability
dose rapamycin
Prior art date
Application number
PL07753937T
Other languages
English (en)
Inventor
David M Kleinman
Thierry Nivaggioli
Mary Gerritsen
David A Weber
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of PL2001466T3 publication Critical patent/PL2001466T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL07753937T 2006-03-23 2007-03-23 Rapamycyna w małej dawce do leczenia chorób związanych z przepuszczalnością naczyń PL2001466T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78581406P 2006-03-23 2006-03-23
EP07753937.7A EP2001466B1 (en) 2006-03-23 2007-03-23 Low-dose rapamycin for the treatment of vascular permeability-related diseases
PCT/US2007/007353 WO2007112052A2 (en) 2006-03-23 2007-03-23 Formulations and methods for vascular permeability-related diseases or conditions

Publications (1)

Publication Number Publication Date
PL2001466T3 true PL2001466T3 (pl) 2016-06-30

Family

ID=38541710

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07753937T PL2001466T3 (pl) 2006-03-23 2007-03-23 Rapamycyna w małej dawce do leczenia chorób związanych z przepuszczalnością naczyń

Country Status (13)

Country Link
US (3) US8222271B2 (pl)
EP (1) EP2001466B1 (pl)
JP (2) JP5506378B2 (pl)
KR (2) KR101520408B1 (pl)
CN (2) CN101443004B (pl)
AU (1) AU2007230964B2 (pl)
BR (1) BRPI0709016A2 (pl)
CA (1) CA2645488C (pl)
DK (1) DK2001466T3 (pl)
ES (1) ES2563288T3 (pl)
HK (1) HK1126427A1 (pl)
PL (1) PL2001466T3 (pl)
WO (1) WO2007112052A2 (pl)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2438544A (en) 2005-02-09 2007-11-28 Cooper Internat Corp Liquid formulations for treatment of diseases or conditions
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
AU2006227116A1 (en) * 2005-03-21 2006-09-28 Santen Pharmaceutical Co., Ltd. Drug delivery systems for treatment of diseases or conditions
CN101605529B (zh) 2006-02-09 2013-03-13 参天制药株式会社 稳定制剂及它们的制备和使用方法
PL2001466T3 (pl) 2006-03-23 2016-06-30 Santen Pharmaceutical Co Ltd Rapamycyna w małej dawce do leczenia chorób związanych z przepuszczalnością naczyń
US20100040669A1 (en) * 2008-08-12 2010-02-18 Higuchi John W Non-Invasive Ocular Delivery of Rapamycin
EP2965763B8 (en) * 2009-04-10 2018-08-15 Haiyan Qi Anti-aging agents
WO2011071535A2 (en) * 2009-12-11 2011-06-16 Mount Sinai School Of Medicine Of New York University Compositions and methods for inhibiting human host cell factors required for influenza virus replication
US8343471B2 (en) 2010-04-30 2013-01-01 Indian Institute Of Technology Bombay Nanoparticulate in-situ gels of TPGS, gellan and PVA as vitreous humor substitutes
EP2704711B1 (en) 2011-05-02 2020-12-02 The Board of Trustees of the Leland Stanford Junior University Use of fk506 for the treatment of pulmonary arterial hypertension
CN102274219A (zh) * 2011-06-27 2011-12-14 苏州大学附属第一医院 雷帕霉素在治疗蛛网膜下腔出血早期脑损伤的应用
US8912215B2 (en) 2011-12-13 2014-12-16 Everon Biosciences, Inc. Rapamycin composition
CA2929181A1 (en) * 2013-11-13 2015-05-21 Novartis Ag Mtor inhibitors for enhancing the immune response
CA2975879A1 (en) 2015-02-05 2016-08-11 Memorial Sloan Kettering Cancer Center Compositions and methods for treatment of edema
MX2017014776A (es) 2015-05-20 2018-02-15 Novartis Ag Combinacion farmaceutica de everolimus con dactolisib.
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
ES2908479T3 (es) 2015-08-26 2022-04-29 Achillion Pharmaceuticals Inc Compuestos para el tratamiento de trastornos inmunitarios e inflamatorios
MX2018003381A (es) 2015-09-18 2018-08-15 Santen Pharmaceutical Co Ltd Profilactico o agente terapeutico para queratitis fungica.
US10695326B2 (en) 2015-09-24 2020-06-30 Drexel University Compositions and methods for treating or preventing dermal disorders
WO2017204298A1 (en) 2016-05-25 2017-11-30 Santen Pharmaceutical Co., Ltd. Use of sirolimus to treat exudative age-related macular degeneration with persistent edema
EP3939591A1 (en) 2016-06-27 2022-01-19 Achillion Pharmaceuticals, Inc. Quinazoline and indole compounds to treat medical disorders
SG11201810618QA (en) 2016-06-30 2019-01-30 Durect Corp Depot formulations
US10682340B2 (en) 2016-06-30 2020-06-16 Durect Corporation Depot formulations
CN106248947A (zh) * 2016-07-21 2016-12-21 中国人民解放军军事医学科学院基础医学研究所 一种哺乳动物高原脑水肿生物标志物及其应用
CN110114070A (zh) 2016-11-23 2019-08-09 诺华公司 使用依维莫司(everolimus)、达托里昔布(dactolisib)或二者增强免疫反应的方法
EP3589628A4 (en) 2017-03-01 2021-03-31 Achillion Pharmaceuticals, Inc. ARYL, HETEROARYL AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISEASES
JP2020520906A (ja) 2017-05-19 2020-07-16 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 肺高血圧症の治療のためのエンザスタウリン及び脆弱性ヒスチジン三連構造(fhit)増加剤
WO2019157516A1 (en) 2018-02-12 2019-08-15 resTORbio, Inc. Combination therapies
KR20210018199A (ko) 2018-03-26 2021-02-17 씨4 테라퓨틱스, 인코포레이티드 이카로스의 분해를 위한 세레블론 결합제
WO2020041301A1 (en) 2018-08-20 2020-02-27 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement factor d medical disorders
CN113365617A (zh) 2018-10-16 2021-09-07 乔治亚州立大学研究基金会股份有限公司 用于医学疾病治疗的一氧化碳前药
JPWO2020175131A1 (ja) * 2019-02-27 2021-12-23 国立大学法人大阪大学 脈管異常治療用外用剤
CN115279370A (zh) 2020-03-05 2022-11-01 C4医药公司 用于brd9的靶向降解的化合物

Family Cites Families (248)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3416530A (en) 1966-03-02 1968-12-17 Richard A. Ness Eyeball medication dispensing tablet
US3630200A (en) 1969-06-09 1971-12-28 Alza Corp Ocular insert
US3828777A (en) 1971-11-08 1974-08-13 Alza Corp Microporous ocular device
US3914402A (en) 1973-06-14 1975-10-21 Alza Corp Ophthalmic dosage form, for releasing medication over time
US3926188A (en) 1974-11-14 1975-12-16 Alza Corp Laminated drug dispenser
US4093709A (en) * 1975-01-28 1978-06-06 Alza Corporation Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates)
US4014335A (en) * 1975-04-21 1977-03-29 Alza Corporation Ocular drug delivery device
FR2382240A1 (fr) 1977-03-03 1978-09-29 Mouls Pierre Dispositif permettant d'instiller des liquides medicamenteux dans l'oeil
US4300557A (en) 1980-01-07 1981-11-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method for treating intraocular malignancies
AU543727B2 (en) 1980-06-02 1985-05-02 Ayerst Mckenna & Harrison Inc. Injectable composition of rapamycin
IT1141715B (it) 1980-06-06 1986-10-08 Sadepan Chimica Spa Collante a base di resina urea-formaldeide additivato con ligninsolfonato di calcio e/o ammonio,resina urea formaldeide modificata con ligninsolfonato di calcio e/o ammonio e metodo di produzione degli stessi,per la preparazione di pannelli agglomerati di legno
US4316885A (en) * 1980-08-25 1982-02-23 Ayerst, Mckenna And Harrison, Inc. Acyl derivatives of rapamycin
US4650803A (en) * 1985-12-06 1987-03-17 University Of Kansas Prodrugs of rapamycin
US5322691A (en) * 1986-10-02 1994-06-21 Sohrab Darougar Ocular insert with anchoring protrusions
US5147647A (en) 1986-10-02 1992-09-15 Sohrab Darougar Ocular insert for the fornix
EP0391909B1 (en) 1987-09-03 1994-08-17 The University Of Georgia Research Foundation, Inc. Ocular cyclosporin composition
US4997652A (en) * 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
US4853224A (en) 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
EP0356399A3 (en) * 1988-08-26 1991-03-20 Sandoz Ag Substituted 4-azatricyclo (22.3.1.04.9) octacos-18-ene derivatives, their preparation and pharmaceutical compositions containing them
US4946450A (en) 1989-04-18 1990-08-07 Biosource Genetics Corporation Glucan/collagen therapeutic eye shields
US5100899A (en) * 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
US5164188A (en) 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
US5883082A (en) * 1990-08-14 1999-03-16 Isis Pharmaceuticals, Inc. Compositions and methods for preventing and treating allograft rejection
US5192773A (en) * 1990-07-02 1993-03-09 Vertex Pharmaceuticals, Inc. Immunosuppressive compounds
DE4022553A1 (de) 1990-07-16 1992-01-23 Hund Helmut Gmbh Vorrichtung zur hochreproduzierbaren applikation definierter volumina von loesungen und suspensionen diagnostisch oder therapeutisch wirksamer substanzen auf der cornea-oberflaeche
JPH04230389A (ja) 1990-07-16 1992-08-19 American Home Prod Corp ラパマイシン誘導体
US5023262A (en) * 1990-08-14 1991-06-11 American Home Products Corporation Hydrogenated rapamycin derivatives
PT98990A (pt) 1990-09-19 1992-08-31 American Home Prod Processo para a preparacao de esteres de acidos carboxilicos de rapamicina
US5290892A (en) * 1990-11-07 1994-03-01 Nestle S.A. Flexible intraocular lenses made from high refractive index polymers
IE65341B1 (en) 1990-11-08 1995-10-18 Fujisawa Pharmaceutical Co Suspensions containing tricyclic compounds
US5378475A (en) * 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US5078999A (en) * 1991-02-22 1992-01-07 American Home Products Corporation Method of treating systemic lupus erythematosus
US5120842A (en) * 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
CA2102241C (en) * 1991-04-26 2003-12-30 Manabu Mochizuki Use of macrolide compounds for eye diseases
US5565560A (en) 1991-05-13 1996-10-15 Merck & Co., Inc. O-Aryl,O-alkyl,O-alkenyl and O-alkynylmacrolides having immunosuppressive activity
US5120727A (en) * 1991-05-29 1992-06-09 American Home Products Corporation Rapamycin dimers
US5120725A (en) * 1991-05-29 1992-06-09 American Home Products Corporation Bicyclic rapamycins
IL102414A (en) * 1991-07-25 1996-08-04 Univ Louisville Res Found Medicinal preparations for the treatment of ocular inflammation, containing rapamycin
US5189042A (en) * 1991-08-22 1993-02-23 Merck & Co. Inc. Fluoromacrolides having immunosuppressive activity
US5457111A (en) 1991-09-05 1995-10-10 Abbott Laboratories Macrocyclic immunomodulators
US5192802A (en) * 1991-09-25 1993-03-09 Mcneil-Ppc, Inc. Bioadhesive pharmaceutical carrier
US5770592A (en) * 1991-11-22 1998-06-23 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization using angiostatic steroids
US5679666A (en) 1991-11-22 1997-10-21 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization by treatment with angiostatic steroids
US5516781A (en) * 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
US5177203A (en) * 1992-03-05 1993-01-05 American Home Products Corporation Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents
AU681579B2 (en) 1992-03-30 1997-09-04 Wyeth Rapamycin formulation for IV injection
US5178635A (en) * 1992-05-04 1993-01-12 Allergan, Inc. Method for determining amount of medication in an implantable device
FR2690846B1 (fr) * 1992-05-05 1995-07-07 Aiache Jean Marc Forme galenique pour administration oculaire et procede de preparation.
WO1994005257A1 (en) 1992-09-08 1994-03-17 Allergan, Inc. Sustained release of ophthalmic drugs from a soluble polymer drug delivery vehicle
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5258389A (en) 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
AU5434094A (en) * 1992-11-18 1994-06-08 Fujisawa Pharmaceutical Co., Ltd. Prolonged-action pharmaceutical preparation
CA2156065A1 (en) 1993-03-17 1994-09-29 Rolf Wagner Macrocyclic amide and urea immunomodulators
GB2278780B (en) 1993-05-27 1998-10-14 Sandoz Ltd Macrolide formulations
US5798355A (en) 1995-06-07 1998-08-25 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity
CA2468375A1 (en) * 1993-07-19 1995-02-02 Angiotech Pharmaceuticals, Inc. Anti-angiogenic compositions, uses and methods
WO1995003009A1 (en) * 1993-07-22 1995-02-02 Oculex Pharmaceuticals, Inc. Method of treatment of macular degeneration
US5536729A (en) 1993-09-30 1996-07-16 American Home Products Corporation Rapamycin formulations for oral administration
US5616588A (en) * 1993-09-30 1997-04-01 American Home Products Corporation Rapamycin formulation for IV injection
US5516770A (en) * 1993-09-30 1996-05-14 American Home Products Corporation Rapamycin formulation for IV injection
IL111004A (en) 1993-09-30 1998-06-15 American Home Prod Oral formulations of rapamycin
US5443505A (en) * 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5527907A (en) * 1993-11-19 1996-06-18 Abbott Laboratories Macrolide immunomodulators
EP0729471A1 (en) 1993-11-19 1996-09-04 Abbott Laboratories Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
EP0734389B1 (en) * 1993-12-17 2000-03-29 Novartis AG Rapamycin derivatives useful as immunosuppressants
US5788687A (en) 1994-02-01 1998-08-04 Caphco, Inc Compositions and devices for controlled release of active ingredients
US5773021A (en) * 1994-03-14 1998-06-30 Vetoquinol S.A. Bioadhesive ophthalmic insert
US5516522A (en) * 1994-03-14 1996-05-14 Board Of Supervisors Of Louisiana State University Biodegradable porous device for long-term drug delivery with constant rate release and method of making the same
JPH09511507A (ja) 1994-04-04 1997-11-18 フリーマン,ウイリアム・アール 上昇した眼圧を治療するためのホスホニルメトキシアルキルヌクレオシドの使用
US5466233A (en) 1994-04-25 1995-11-14 Escalon Ophthalmics, Inc. Tack for intraocular drug delivery and method for inserting and removing same
US5621108A (en) * 1994-12-05 1997-04-15 Trustees Of The University Of Pennsylvania Processes and intermediates for preparing macrocycles
US5725493A (en) 1994-12-12 1998-03-10 Avery; Robert Logan Intravitreal medicine delivery
EP0957949B1 (en) 1995-05-14 2004-08-04 Optonol Ltd. Intraocular implant, delivery device, and method of implantation
US5614547A (en) * 1995-06-07 1997-03-25 Guilford Pharmaceuticals Inc. Small molecule inhibitors of rotamase enzyme
US5696135A (en) 1995-06-07 1997-12-09 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth
CA2219080A1 (en) 1995-06-07 1996-12-27 Ariad Gene Therapeutics, Inc. Rapamycin-based regulation of biological events
US6037370A (en) 1995-06-08 2000-03-14 Vertex Pharmaceuticals Incorporated Methods and compositions for stimulating neurite growth
FR2736550B1 (fr) 1995-07-14 1998-07-24 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
JPH0930966A (ja) 1995-07-24 1997-02-04 Gakuzo Tamura 眼科用新規製剤
EP0851753B1 (en) 1995-09-19 2003-11-19 Fujisawa Pharmaceutical Co., Ltd. Aerosol compositions
US5773019A (en) * 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
WO1997016068A1 (en) 1995-10-31 1997-05-09 Merck & Co., Inc. Triterpene derivatives with immunosuppressant activity
GB9601120D0 (en) * 1996-01-19 1996-03-20 Sandoz Ltd Organic compounds
DE69733338T2 (de) 1996-02-13 2006-03-16 G.D. Searle & Co., Chicago Zubereitungen, enthaltend einen cyclooxygenase-2-inhibitor und einen leukotrien-b4-rezeptor-antagonisten
US5743274A (en) * 1996-03-18 1998-04-28 Peyman; Gholam A. Macular bandage for use in the treatment of subretinal neovascular members
US5904144A (en) * 1996-03-22 1999-05-18 Cytotherapeutics, Inc. Method for treating ophthalmic diseases
JP3309175B2 (ja) 1996-03-25 2002-07-29 参天製薬株式会社 タンパク性薬物含有強膜プラグ
JPH09315954A (ja) 1996-05-30 1997-12-09 Kita:Kk 眼科手術後の眼組織混濁防止剤。
GB9710962D0 (en) * 1997-05-28 1997-07-23 Univ Cambridge Tech Polyketides and their synthesis
RU2123314C1 (ru) 1996-06-27 1998-12-20 Павлова Татьяна Вячеславовна Способ постановки ирригационной системы в теноново пространство
PT1208847E (pt) 1996-07-30 2007-07-24 Novartis Ag Composições farmacêuticas para o tratamento da rejeição de transplantes, doenças autoimunes ou inflamatórias compreendendo ciclosporina a e 40-0-(2-hidroxietil)-rapamicina
US6007510A (en) 1996-10-25 1999-12-28 Anamed, Inc. Implantable devices and methods for controlling the flow of fluids within the body
US6142969A (en) 1996-10-25 2000-11-07 Anamed, Inc. Sutureless implantable device and method for treatment of glaucoma
AUPO427196A0 (en) 1996-12-19 1997-01-23 University Of Sydney, The A method for preventing or controlling cataract
JPH10218787A (ja) 1997-02-06 1998-08-18 Akio Okamoto 神経栄養因子による眼科用組成物
TW450810B (en) * 1997-02-20 2001-08-21 Fujisawa Pharmaceutical Co Macrolides antibiotic pharmaceutical composition for preventing and treating skin diseases
US6273913B1 (en) * 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
WO1999007418A2 (en) 1997-08-11 1999-02-18 Allergan Sales, Inc. Sterile bioerodible implant device with improved biocompatability and method
US5902598A (en) 1997-08-28 1999-05-11 Control Delivery Systems, Inc. Sustained release drug delivery devices
US6342507B1 (en) 1997-09-05 2002-01-29 Isotechnika, Inc. Deuterated rapamycin compounds, method and uses thereof
US6890546B2 (en) * 1998-09-24 2005-05-10 Abbott Laboratories Medical devices containing rapamycin analogs
US20060198867A1 (en) 1997-09-25 2006-09-07 Abbott Laboratories, Inc. Compositions and methods of administering rapamycin analogs using medical devices for long-term efficacy
US6015815A (en) 1997-09-26 2000-01-18 Abbott Laboratories Tetrazole-containing rapamycin analogs with shortened half-lives
US20030190286A1 (en) 1997-10-01 2003-10-09 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating allergies or asthma
US20020052390A1 (en) 1997-10-22 2002-05-02 Jens Ponikau Methods and materials for treating and preventing inflammation of mucosal tissue
ZA989885B (en) 1997-10-31 1999-05-05 Abbott Lab Use of macrolides for the treatment of cancer and macular degeneration
CZ287497B6 (cs) 1997-12-30 2000-12-13 Galena, A. S. Topické oční přípravky s imunosupresivními látkami
WO1999037667A1 (en) 1998-01-23 1999-07-29 Microcide Pharmaceuticals, Inc. Efflux pump inhibitors
DE19810655A1 (de) 1998-03-12 1999-09-16 Univ Eberhard Karls Arzneimittel mit einem Gehalt an Ciclosporin
EP1806135A3 (en) 1998-03-13 2010-11-24 The Johns Hopkins University School Of Medicine The use of a protein tyrosine inhibitor such as genistein in the treatment of diabetic retinopathy or ocular inflammation
AU3980499A (en) 1998-05-11 1999-11-29 Endowment for Research in Human Biology, Inc., The Use of neomycin for treating angiogenesis-related diseases
US6399629B1 (en) * 1998-06-01 2002-06-04 Microcide Pharmaceuticals, Inc. Efflux pump inhibitors
AU748867B2 (en) 1998-07-24 2002-06-13 Jagotec Ag Medicinal aerosol formulations
US6378526B1 (en) * 1998-08-03 2002-04-30 Insite Vision, Incorporated Methods of ophthalmic administration
US7338976B1 (en) 1998-08-14 2008-03-04 Gpi Nil Holdings, Inc. Heterocyclic esters or amides for vision and memory disorders
US6376517B1 (en) 1998-08-14 2002-04-23 Gpi Nil Holdings, Inc. Pipecolic acid derivatives for vision and memory disorders
US6384056B1 (en) 1998-08-14 2002-05-07 Gpi Nil Holdings, Inc. Heterocyclic thioesters or ketones for vision and memory disorders
US6303637B1 (en) 1998-10-30 2001-10-16 Merck & Co., Inc. Heterocyclic potassium channel inhibitors
US6632836B1 (en) 1998-10-30 2003-10-14 Merck & Co., Inc. Carbocyclic potassium channel inhibitors
CA2351658C (en) 1998-11-17 2006-07-11 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating post traumatic stress disorder
GB9826882D0 (en) 1998-12-07 1999-01-27 Novartis Ag Organic compounds
US6399655B1 (en) 1998-12-22 2002-06-04 Johns Hopkins University, School Of Medicine Method for the prophylactic treatment of cataracts
EA005815B1 (ru) 1998-12-23 2005-06-30 Джи.Ди.Сирл Ллс Комбинация ингибиторов транспорта желчных кислот в подвздошной кишке и ингибиторов белка, переносящего эфиры холестерина, для сердечно-сосудистых показаний
US6864232B1 (en) * 1998-12-24 2005-03-08 Sucampo Ag Agent for treating visual cell function disorder
WO2000038703A1 (en) 1998-12-24 2000-07-06 R-Tech Ueno, Ltd. Agent for treating visual cell function disorder
EP1154691A4 (en) 1999-01-05 2004-07-07 Massachusetts Eye & Ear Infirm TARGETED ADMINISTRATION OF REGULATED RELEASE MEDICINE TO RETINA AND CHOROID THROUGH SCLEROTIC
US6706283B1 (en) 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6217895B1 (en) * 1999-03-22 2001-04-17 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US6239113B1 (en) * 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
US6254860B1 (en) * 1999-04-13 2001-07-03 Allergan Sales, Inc. Ocular treatment using cyclosporin-A derivatives
US7063857B1 (en) 1999-04-30 2006-06-20 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
BR0011225A (pt) 1999-04-30 2002-03-19 Sucampo Ag Agente para tratar de olhos secos, seu método e uso
US6576224B1 (en) * 1999-07-06 2003-06-10 Sinuspharma, Inc. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
JP2001064198A (ja) 1999-08-24 2001-03-13 Teika Seiyaku Kk 角膜疾患治療剤
JP2003512314A (ja) 1999-10-18 2003-04-02 藤沢薬品工業株式会社 リポソーム製剤の製造方法
ES2240180T3 (es) 1999-10-21 2005-10-16 Alcon Inc. Administracion sub-tenon de medicamentos.
US6416777B1 (en) 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
DE60040876D1 (de) 1999-10-21 2009-01-02 Alcon Inc Medikamentenzuführeinrichtung
US6331313B1 (en) 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
EP1225879A2 (en) * 1999-10-22 2002-07-31 Orbon Corporation Ophthalmic formulation of dopamine antagonists
CA2387889A1 (en) 1999-10-22 2001-05-03 Biogen, Inc. Use of a cd40:cd154 binding interruptor to treat immunological complications of the eye
WO2001034816A1 (en) 1999-10-29 2001-05-17 Kosan Biosciences, Inc. Rapamycin analogs
RU2149615C1 (ru) 1999-11-10 2000-05-27 Нестеров Аркадий Павлович Способ введения лекарственных препаратов при заболеваниях заднего отрезка глаза
US6531464B1 (en) 1999-12-07 2003-03-11 Inotek Pharmaceutical Corporation Methods for the treatment of neurodegenerative disorders using substituted phenanthridinone derivatives
EA006402B1 (ru) 1999-12-23 2005-12-29 Пфайзер Продактс Инк. Комбинация лекарства и целлюлозного полимера, повышающего концентрацию; способ введения лекарства и водный раствор (варианты)
US6489335B2 (en) 2000-02-18 2002-12-03 Gholam A. Peyman Treatment of ocular disease
US20030018044A1 (en) * 2000-02-18 2003-01-23 Peyman Gholam A. Treatment of ocular disease
ES2206363T3 (es) 2000-04-07 2004-05-16 Laboratoire Medidom S.A. Formulaciones oftalmicas a base de ciclosporina, de acido hialuronico y de polisorbato.
US6375972B1 (en) * 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
FR2809619B1 (fr) 2000-06-06 2004-09-24 Pharmatop Nouvelles formulations aqueuses de principes actifs sensibles a l'oxydation et leur procede d'obtention
CN1127955C (zh) 2000-07-07 2003-11-19 中山医科大学中山眼科中心 一种眼前段及眼表免疫相关性疾病治疗药物
CN1204919C (zh) 2000-08-30 2005-06-08 中国科学院化学研究所 长效环孢素眼内释药体系
EP1992317B1 (en) * 2000-08-30 2012-02-29 Johns Hopkins University Devices for intraocular drug delivery
US6696483B2 (en) 2000-10-03 2004-02-24 Oncopharmaceutical, Inc. Inhibitors of angiogenesis and tumor growth for local and systemic administration
US6534693B2 (en) * 2000-11-06 2003-03-18 Afmedica, Inc. Surgically implanted devices having reduced scar tissue formation
US20040018228A1 (en) * 2000-11-06 2004-01-29 Afmedica, Inc. Compositions and methods for reducing scar tissue formation
US20050084514A1 (en) * 2000-11-06 2005-04-21 Afmedica, Inc. Combination drug therapy for reducing scar tissue formation
EP1339438B1 (en) 2000-11-29 2005-10-19 Allergan Inc. Preventing transplant rejection in the eye
US20020086051A1 (en) 2001-01-03 2002-07-04 Santos Viscasillas Sustained release drug delivery devices with coated drug cores
ATE481097T1 (de) 2001-01-16 2010-10-15 Vascular Therapies Llc Implantierbare vorrichtung enthaltend resorbierbares matrixmaterial und antiproliferative wirkstoffe zur vorbeugung oder behandlung von versagen vaskulärer hämodialysezugänge und anderer vaskulärer transplantate
US7181287B2 (en) * 2001-02-13 2007-02-20 Second Sight Medical Products, Inc. Implantable drug delivery device
DK3342411T3 (da) 2001-02-19 2019-09-02 Novartis Pharma Ag Rapamycinderivat til behandling af pancreascancer
US6777000B2 (en) 2001-02-28 2004-08-17 Carrington Laboratories, Inc. In-situ gel formation of pectin
US6713081B2 (en) 2001-03-15 2004-03-30 The United States Of America As Represented By The Department Of Health And Human Services Ocular therapeutic agent delivery devices and methods for making and using such devices
AR033151A1 (es) * 2001-04-12 2003-12-03 Sucampo Pharmaceuticals Inc Agente para el tratamiento oftalmico topico de las enfermedades inflamatorias oculares
EP1387671A1 (en) * 2001-05-03 2004-02-11 MASSACHUSETTS EYE & EAR INFIRMARY Implantable drug delivery device and use thereof
JP2002332225A (ja) 2001-05-09 2002-11-22 Lion Corp 眼科用組成物
JP2003009899A (ja) * 2001-05-28 2003-01-14 New Industry Research Organization 化合物のスクリーニング方法
EP1404297B1 (en) 2001-06-12 2011-04-27 The Johns Hopkins University School Of Medicine Reservoir device for intraocular drug delivery
US7034037B2 (en) * 2001-06-29 2006-04-25 Ethicon, Inc. Compositions and medical devices utilizing bioabsorbable polymeric waxes and rapamycin
WO2003004098A1 (en) * 2001-07-06 2003-01-16 Sucampo Ag Composition for topical administration comprising an interleukin-2 inhibitor and an antimicrobial agent
TWI324925B (en) 2001-08-23 2010-05-21 Novartis Ag Ophthalmic composition
US6812220B2 (en) 2001-08-29 2004-11-02 University Of British Columbia Pharmaceutical compositions and methods relating to fucans
GB0122318D0 (en) 2001-09-14 2001-11-07 Novartis Ag Organic compounds
US6656460B2 (en) 2001-11-01 2003-12-02 Yissum Research Development Method and composition for dry eye treatment
US6939376B2 (en) 2001-11-05 2005-09-06 Sun Biomedical, Ltd. Drug-delivery endovascular stent and method for treating restenosis
CN1582156A (zh) 2001-11-09 2005-02-16 眼科技术药物公司 眼新血管疾病的治疗方法
US6663880B1 (en) * 2001-11-30 2003-12-16 Advanced Cardiovascular Systems, Inc. Permeabilizing reagents to increase drug delivery and a method of local delivery
AU2002231703B2 (en) 2001-12-14 2007-03-29 Jagotec Ag Pharmaceutical formulation comprising cyclosporin and use thereof
GB0200429D0 (en) * 2002-01-09 2002-02-27 Novartis Ag Organic compounds
CA2478424A1 (en) 2002-03-01 2003-09-12 Novagali Pharma Sa Self emulsifying drug delivery systems for poorly soluble drugs
US20030175355A1 (en) 2002-03-07 2003-09-18 Tobyn Michael John Fast melt multiparticulate formulations for oral delivery
CN1456350A (zh) 2002-05-10 2003-11-19 刘继东 环孢素眼用凝胶
US20040057958A1 (en) * 2002-05-17 2004-03-25 Waggoner David W. Immunogenicity-enhancing carriers and compositions thereof and methods of using the same
US7026374B2 (en) * 2002-06-25 2006-04-11 Aruna Nathan Injectable microdispersions for medical applications
DK1589031T3 (da) 2002-07-16 2007-12-10 Biotica Tech Ltd Fremstillingaf polyketider og andre naturlige produkter
SI1553940T1 (sl) 2002-07-30 2008-08-31 Wyeth Corp Parenteralne farmacevtske oblike, ki vsebujejo rapamicin-hidroksiester
CA2495103A1 (en) 2002-08-09 2004-02-19 Sucampo Pharmaceuticals, Inc. Pharmaceutical compositions comprising fk506 derivatives and their use for the treatment of allergic diseases
DK1539157T3 (da) 2002-09-18 2013-10-07 Univ Pennsylvania Fremgangsmåde til hæmning af choroidal neovaskularisering
US20050143363A1 (en) 2002-09-29 2005-06-30 Innorx, Inc. Method for subretinal administration of therapeutics including steroids; method for localizing pharmacodynamic action at the choroid of the retina; and related methods for treatment and/or prevention of retinal diseases
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
WO2004060283A2 (en) 2002-12-16 2004-07-22 Nitromed, Inc. Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use
AR042890A1 (es) 2003-01-16 2005-07-06 Sucampo Pharmaceuticals Inc Metodo de tratamiento del ojo seco con una composicion oftalmica que contiene un compuesto macrolido
WO2004074445A2 (en) 2003-02-17 2004-09-02 Cold Spring Harbor Laboratory Model for studying the role of genes in tumor resistance to chemotherapy
US20050255144A1 (en) 2003-04-09 2005-11-17 Directcontact Llc Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases
US20050074497A1 (en) 2003-04-09 2005-04-07 Schultz Clyde L. Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
WO2004096261A1 (es) 2003-05-02 2004-11-11 Arturo Jimenez Bayardo Metodo para preparar una solucion acuosa de ciclosporina-a y solucion acuosa resultante
US7160867B2 (en) * 2003-05-16 2007-01-09 Isotechnika, Inc. Rapamycin carbohydrate derivatives
EP2044959A1 (en) * 2003-06-26 2009-04-08 pSivida Inc In-situ gelling drug delivery system
US7083802B2 (en) 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
EP1510206A1 (en) 2003-08-29 2005-03-02 Novagali Pharma SA Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs
WO2005027906A1 (en) * 2003-09-18 2005-03-31 Macusight, Inc. Transscleral delivery
US7083803B2 (en) 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
US20050181018A1 (en) 2003-09-19 2005-08-18 Peyman Gholam A. Ocular drug delivery
US7087237B2 (en) 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
EP1681983A4 (en) 2003-10-14 2008-12-10 Monogram Biosciences Inc RECEPTOR TYROSINE KINASE SIGNAL PATH ANALYSIS FOR DIAGNOSIS AND THERAPY
EP1684819A2 (en) 2003-11-20 2006-08-02 Angiotech International Ag Polymer compositions and methods for their use
AU2004293463A1 (en) 2003-11-20 2005-06-09 Angiotech International Ag Implantable sensors and implantable pumps and anti-scarring agents
US7186518B2 (en) * 2003-11-21 2007-03-06 Dade Behring Inc. Method and composition useful for determining FK 506
US8529939B2 (en) 2003-12-08 2013-09-10 Gel-Del Technologies, Inc. Mucoadhesive drug delivery devices and methods of making and using thereof
US20050256081A1 (en) 2004-02-26 2005-11-17 Peyman Gholam A Tetracycline derivatives for the treatment of ocular pathologies
US20050266442A1 (en) * 2004-03-25 2005-12-01 Rachel Squillace Immortalized human Tuberous Sclerosis null angiomyolipoma cell and method of use thereof
US7846940B2 (en) 2004-03-31 2010-12-07 Cordis Corporation Solution formulations of sirolimus and its analogs for CAD treatment
PT1755616E (pt) 2004-04-08 2013-11-18 Advanced Ocular Systems Ltd Tratamento de condições patológicas oftálmicas
US20060182783A1 (en) 2004-04-30 2006-08-17 Allergan, Inc. Sustained release intraocular drug delivery systems
WO2005110374A1 (en) 2004-04-30 2005-11-24 Allergan, Inc. Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component
US20050250804A1 (en) 2004-05-06 2005-11-10 Glenmark Pharmaceuticals Limited Pharmaceutical gel formulations
WO2006002399A2 (en) 2004-06-24 2006-01-05 Surmodics, Inc. Biodegradable implantable medical devices, methods and systems
WO2006002366A2 (en) 2004-06-24 2006-01-05 Surmodics, Inc. Biodegradable ocular devices, methods and systems
US20080124400A1 (en) 2004-06-24 2008-05-29 Angiotech International Ag Microparticles With High Loadings Of A Bioactive Agent
JP2008512350A (ja) * 2004-07-01 2008-04-24 イェール ユニバーシティ 標的化され、そして高密度で薬物が負荷されるポリマー性物質
US20060110428A1 (en) 2004-07-02 2006-05-25 Eugene Dejuan Methods and devices for the treatment of ocular conditions
WO2006020755A2 (en) 2004-08-10 2006-02-23 Beth Israel Deaconess Medical Center, Inc. Methods for identifying inhibitors of the mtor pathway as diabetes therapeutics
US20060034891A1 (en) * 2004-08-12 2006-02-16 Laurie Lawin Biodegradable controlled release bioactive agent delivery device
AR050374A1 (es) 2004-08-20 2006-10-18 Wyeth Corp Forma polimorfica de rafampicina
DE602005024012D1 (de) 2004-08-27 2010-11-18 Cordis Corp Lösungsmittelfreies amorphes rapamycin
EP2452670A1 (en) * 2004-10-01 2012-05-16 Ramscor, Inc. Conveniently implantable sustained release drug compositions
WO2006041942A2 (en) 2004-10-04 2006-04-20 Qlt Usa, Inc. Ocular delivery of polymeric delivery formulations
EP1843805A4 (en) 2004-11-09 2015-05-06 Angiotech Pharm Inc ANTIMICROBIAL NEEDLE COATING FOR ADVANCED INFUSION
GB2438544A (en) 2005-02-09 2007-11-28 Cooper Internat Corp Liquid formulations for treatment of diseases or conditions
GB0504995D0 (en) * 2005-03-11 2005-04-20 Biotica Tech Ltd Use of a compound
AU2006227116A1 (en) 2005-03-21 2006-09-28 Santen Pharmaceutical Co., Ltd. Drug delivery systems for treatment of diseases or conditions
US20060216288A1 (en) 2005-03-22 2006-09-28 Amgen Inc Combinations for the treatment of cancer
JP2008535847A (ja) 2005-04-08 2008-09-04 サーモディクス,インコーポレイティド 網膜下に送達するための持続放出インプラント
NZ563003A (en) 2005-04-27 2011-03-31 Univ Florida Use of a farnesyl transferase inhibitor to enhance autophagic protein degradation in protein conformation disorders
US20060247265A1 (en) 2005-04-28 2006-11-02 Clackson Timothy P Therapies for treating disorders of the eye
AU2006255183B2 (en) 2005-06-08 2012-02-02 Centocor, Inc. A cellular therapy for ocular degeneration
PL1904056T3 (pl) 2005-07-18 2009-09-30 Minu Llc Zastosowanie makrolidu do przywracania czucia rogówkowego
US20070014760A1 (en) * 2005-07-18 2007-01-18 Peyman Gholam A Enhanced recovery following ocular surgery
US20070134244A1 (en) 2005-10-14 2007-06-14 Alcon, Inc. Combination treatment for pathologic ocular angiogenesis
DE102006051512A1 (de) 2005-12-06 2007-06-14 Pari GmbH Spezialisten für effektive Inhalation Pharmazeutische Medikamentenzusammensetzungen mit Cyclosporin
WO2007083316A2 (en) 2006-01-23 2007-07-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem Microspheres comprising nanocapsules containing a lipophilic drug
CN101605529B (zh) 2006-02-09 2013-03-13 参天制药株式会社 稳定制剂及它们的制备和使用方法
EP1996021B1 (en) 2006-02-28 2017-12-13 Paloma Pharmaceuticals, Inc. Compositions and methods to treat diseases characterized by cellular proliferation and angiogenesis
PL2001466T3 (pl) 2006-03-23 2016-06-30 Santen Pharmaceutical Co Ltd Rapamycyna w małej dawce do leczenia chorób związanych z przepuszczalnością naczyń

Also Published As

Publication number Publication date
CN101443004B (zh) 2013-03-06
HK1126427A1 (zh) 2009-09-04
JP5506378B2 (ja) 2014-05-28
CN101443004A (zh) 2009-05-27
US9452156B2 (en) 2016-09-27
US20150265581A1 (en) 2015-09-24
CN103127100A (zh) 2013-06-05
AU2007230964B2 (en) 2012-07-19
US20120329759A1 (en) 2012-12-27
AU2007230964A1 (en) 2007-10-04
BRPI0709016A2 (pt) 2011-06-21
KR101468941B1 (ko) 2014-12-04
KR101520408B1 (ko) 2015-05-14
KR20140108342A (ko) 2014-09-05
ES2563288T3 (es) 2016-03-14
JP5860013B2 (ja) 2016-02-16
US8222271B2 (en) 2012-07-17
WO2007112052A2 (en) 2007-10-04
JP2013237712A (ja) 2013-11-28
US8486960B2 (en) 2013-07-16
JP2009530406A (ja) 2009-08-27
CA2645488C (en) 2014-09-02
CA2645488A1 (en) 2007-10-04
KR20090013761A (ko) 2009-02-05
DK2001466T3 (en) 2016-02-29
WO2007112052A3 (en) 2008-04-03
US20070265294A1 (en) 2007-11-15
EP2001466A2 (en) 2008-12-17
EP2001466B1 (en) 2016-01-06

Similar Documents

Publication Publication Date Title
PL2001466T3 (pl) Rapamycyna w małej dawce do leczenia chorób związanych z przepuszczalnością naczyń
ZA200707591B (en) Dihyrothienopyrimidines for the treatment of inflammatory diseases
EP1883444A4 (en) SELF-CONTAINING CATHETER FOR CLINICAL IMPLANTATION
SI2001892T1 (sl) Spojine imidazolotiazol za zdravljenje proliferacijskih bolezni
ZA200703601B (en) Medicaments for the treatment or prevention of fibriotic diseases
IL193747A0 (en) New therapeutic combinations for the treatment of depression
HK1130208A1 (en) Alpha-msh derivatives for the treatment of photodermatoses -msh
HK1206262A1 (en) Implants for the treatment of dopamine associated states
PL2056863T3 (pl) Leczenie chorób oczu
PT1998730T (pt) Novo sistema de suporte para o tratamento e prevenção de doenças das veias
EP2217238A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF DISEASES RELATED TO PROTEINURIA
GB0909297D0 (en) Composition for the treatment of skin conditions
EP2091480A4 (en) SYSTEM FOR THE TREATMENT OF HEART TISSUE
SI2234631T1 (sl) Spojine in postopki za zdravljenje ĺ˝ilne bolezni
IL188787A (en) Preparations for the treatment of diabetic eye complications
GB0715790D0 (en) Drug combination for the treatment of sialorrhoea
IL192933A0 (en) Benzoisoindole derivatives for the treatment of pain
GB0620695D0 (en) Composition and methods for the treatment of nurdegenerative disease
GB0428218D0 (en) Medicament for Treatment of Inflammatory Diseases
GB0602857D0 (en) The treatment of sialorrhoea
AP2007003952A0 (en) Use of an anti-atherothrombotic compound inobtaining medicaments intended for the treatment of vascular disorders
ZA200806180B (en) Benzoisoindole derivatives for the treatment of pain
AU2005900589A0 (en) Soy-derived products for the treatment of vascular diseases
IL194261A0 (en) S-alkylisothiouronium derivatives for the treatment of inflammatory diseases
GB0618309D0 (en) Compositions and methods for the treatment of disease